Search Results - "Gilloteau, I."

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study by Long, G.V., Atkinson, V., Ascierto, P.A., Robert, C., Hassel, J.C., Rutkowski, P., Savage, K.J., Taylor, F., Coon, C., Gilloteau, I., Dastani, H.B., Waxman, I.M., Abernethy, A.P.

“…Nivolumab has shown significant survival benefit and a favorable safety profile compared with dacarbazine chemotherapy among treatment-naïve patients with…”
Get full text

A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey by Griffiths, C.E.M., Jo, S.‐J., Naldi, L., Romiti, R., Guevara‐Sangines, E., Howe, T., Pietri, G., Gilloteau, I., Richardson, C., Tian, H., Augustin, M.

“…Summary Background Psoriasis is a chronic, immune‐mediated disease, characterized by symptoms that include itching and skin pain and is often associated with…”
Get full text

Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate‐to‐severe psoriasis in five European countries by Augustin, M., Vietri, J., Tian, H., Gilloteau, I.

“…Background Moderate‐to‐severe psoriasis is associated with reduced health‐related quality of life (HRQoL). Individuals with psoriasis are at increased risk for…”
Get full text

Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study by Bissonnette, R., Luger, T., Thaçi, D., Toth, D., Messina, I., You, R., Guana, A., Fox, T., Papavassilis, C., Gilloteau, I., Mrowietz, U.

“…Summary Background Secukinumab has demonstrated significant efficacy with a good safety profile through 1 year in plaque psoriasis. Given the chronic nature of…”
Get full text

Cost‐effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany by Augustin, M., McBride, D., Gilloteau, I., O'Neill, C., Neidhardt, K., Graham, C. N.

“…Background Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin 17A, has demonstrated strong and sustained efficacy in…”
Get full text

Patient–dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real‐world multinational survey by Griffiths, C.E.M., Augustin, M., Naldi, L., Romiti, R., Guevara‐Sangines, E., Howe, T., Pietri, G., Gilloteau, I., Richardson, C., Tian, H., Jo, S.J.

“…Background Psoriasis is a chronic immune‐mediated inflammatory disease, which often requires lifelong treatment. A strong partnership between the patient and…”
Get full text

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom by Warren, R.B., Halliday, A., Graham, C.N., Gilloteau, I., Miles, L., McBride, D.

“…Background Psoriasis causes work productivity impairment that increases with disease severity. Whether differential treatment efficacy translates into…”
Get full text

Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis by Stull, D.E., Griffiths, C.E.M., Gilloteau, I., Zhao, Y., Guana, A., Finlay, A.Y., Sherif, B., Houghton, K., Puig, L.

“…Summary Background The appearance and lifelong, chronic nature of psoriasis result in considerable burden to patients, such as sleep impairment, depressive…”
Get full text

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study by Blauvelt, A., Reich, K., Mehlis, S., Vanaclocha, F., Sofen, H., Abramovits, W., Zhao, Y., Gilloteau, I., Davenport, E., Williams, N., Guana, A., Tyring, S.

“…Background Psoriasis can greatly impact patients’ lives by influencing clothing worn as well as by impairing sexual functioning. Secukinumab, a human…”
Get full text

3331 Quality of survival (QoS) concept framework to assess the quality of prolonged life in advanced melanoma (MEL): Principles and application related to treatment with nivolumab (NIVO) by Fallowfield, L, Nadler, E, Abernethy, A.P, Gilloteau, I, Greaney, M, Gater, A, Orsini, L, Subar, M, Dastani, H.B, Lyman, G.H

Get full text

1222 Long-term clinical experiences of patients (pts) with non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) or metastatic melanoma (MEL): A SEER-Medicare analysis by Nadler, E, Ashaye, A, Stokes, M, Yang, S, Xu, Y, Berger, A, Shaw, J.W, Gilloteau, I, Abernethy, A.P

Get full text

Assessing the Burden of Caregiving for Patients with Lung Cancer in Europe by Goren, A, Gilloteau, I, Penrod, J.R, Jassem, J

Get full text

Rates, Timing, and Costs of Short-Term Disability (Std) and Long-Term Disability (Ltd) in Patients With Newly Diagnosed Advanced Melanoma by Hallmeyer, S, Gilloteau, I, Limone, B, Johnson, W, Malangone-Monaco, E

Get full text

The Relative Clinical and Economic Value of Ipilimumab as First-Line Treatment of Metastatic Melanoma Versus Other Anti-Cancer Agents for Metastatic Diseases by Abernethy, A.P, Kotapati, S, Gilloteau, I, Karweit, J, Wolfe, S

Get full text

PCN63 The Relative Value of Dasatinib Versus Imatinib as First-Line Treatment for Chronic Myeloid Leukemia by Betegon, L, Gilloteau, I, Martin, P, Woolmore, A, Oyagüez, I

Get full text

Psoriasis: clinical and epidemiological features and therapy issues by Bakulev, A. L., Fitileva, T. V., Novodezerkina, E. А., Gilloteau, I., Tian, Н., Howe, T., Pietri, G.

“…Aim. This study sets out to establish the demographic and clinical features of psoriasis and its co-morbidities; to describe approaches to treating patients in…”
Get full text

PSY38 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 400mg Daily in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML) by Mealing, S, Taylor, M, Scott, D, Clark, J, Mckenna, M, Lebmeier, M, Gilloteau, I, Davis, C

Get full text

PCN189 The Use of Parametric Survival Analysis to Predict Progression Free and Overall Survival of Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients by Mealing, S, Scott, D, Taylor, M, Clark, J, Wang, Q, Davis, C, Gilloteau, I

Get full text

PMS29 Abatacept or Infliximab for Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Trial-Based and Real-Life Cost-Consequence Analysis by Benucci, M, Stam, W, Gilloteau, I, Crocchiolo, D, Sennfält, K, Leclerc, A, Bengtsson, N, Maetzel, A, Lucioni, C

Get full text

PBI24 SECUKINUMAB VS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM AN ALGERIAN PERSPECTIVE by Mestouri, A., Kooli, A., Bouchaour, N., Gilloteau, I.

Get full text